Natural language processing (NLP) is a computer technology that uses language cues and context to interpret findings and mine large databases to identify desired clinical
BE
BE
Using AI To Identify Patients With Barrett’s Esophagus and Dysplasia From Pathology Reports
Majority of At-Risk Patients Not Screened for Barrett’s Esophagus
The current screening model for Barrett’s esophagus (BE) has limitations because patients need to be identified by their primary care physician and then referred to
Optimum Barrett’s Inspection Time Is Critical for a High-Quality Endoscopy
Endoscopic surveillance of Barrett’s esophagus (BE) is recommended to reduce mortality and morbidity related to esophageal adenocarcinoma. A thorough endoscopic inspection of a BE segment
Artificial Intelligence Continues To Be Impressive for Characterization of Barrett’s Neoplasia
Barrett’s esophagus (BE)-related neoplasia is frequently missed during upper endoscopy, and characterization of mucosal changes may help in its detection. The primary aim of this
Artificial Intelligence Beats General Endoscopists for the Detection of Barrett’s Neoplasia
Barrett’s esophagus (BE) is a precancerous condition that can lead to the development of dysplasia and esophageal adenocarcinoma (neoplasia). Since neoplasia can present as subtle
Genetic Risk Loci, Biomarkers, and Lifestyle Risk Factors in Barrett’s Esophagus and Cancer
Genome-wide association studies (GWAS) involve scanning the DNA of a large cohort to identify any genetic variants associated with the disease in question. Previous GWAS
Artificial Intelligence Can Help Extract Dysplasia Diagnoses From Electronic Health Records
Natural language processing (NLP) is a branch of artificial intelligence (AI) systems that involves teaching computers the ability to understand written text like how humans
Healing of Mucosal Ablation Areas After Radiofrequency Ablation in Patients With Barrett’s Esophagus
Endoscopic therapy for patients with neoplastic Barrett’s esophagus (BE) involves resection followed by mucosal ablation. Radiofrequency ablation (RFA) of the flat BE mucosa leads to
Endoscopic Submucosal Dissection Plus Radiofrequency Ablation Exhibits High Eradication Rates in Patients With Barrett’s Esophagus
Current strategies for the endoscopic treatment of Barrett’s esophagus (BE) focus on resection of nodular lesions within BE and then the ablation of the flat
Artificial Intelligence Detects Dysplasia in Histopathology Slides From Patients With Barrett’s Esophagus
The degree of dysplasia in patients with Barrett’s esophagus (BE) is key to determining the application of BE endoscopic therapy and assigning surveillance intervals. Multiple
Poor Squamous Regeneration After Barrett’s Endoscopic Therapy Increases Risk for Treatment Failure and Disease Progression
A small subset of patients who undergo Barrett’s endoscopic therapy (BET) using radiofrequency ablation (RFA) will have evidence of poor mucosal healing (mucosal edema, ulcers,
Progression in Barrett’s Esophagus Score Can Be Used for Estimating Neoplastic Progression
Barrett’s esophagus (BE) is a known precancerous lesion for esophageal dysplasia and adenocarcinoma (EAC); however, it is unclear who will progress to high-grade dysplasia (HGD)
Endoscopic Submucosal Dissection Use Changes Histologic Diagnosis in More Than Half of All Patients With Visible Barrett’s Esophagus Neoplasia
Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have emerged as important treatment techniques for patients with visible lesions in Barrett’s esophagus (BE). Whereas
Barrett’s Endoscopic Therapy Using Hybrid-Argon Plasma Coagulation Is Safe and Effective
Endoscopic therapy for Barrett’s esophagus (BE) usually involves resection of visible lesions by endoscopic mucosal resection followed by mucosal ablation using radio frequency ablation. Hybrid
Cryoballoon Ablation Has Similar Efficacy to but Higher Stricture Rates Than Radiofrequency Ablation in Barrett’s Endoscopic Therapy
Radiofrequency ablation (RFA) is widely utilized in the treatment of neoplastic Barrett’s esophagus (BE) after endoscopic resection of all visible lesions. Cryotherapy is another form
Barrett’s Esophagus-Specific Training Improves Adherence to Diagnosis and Treatment Guidelines
The accurate diagnosis and management of patients with Barrett’s esophagus (BE) are important for the early recognition and minimally invasive treatment of BE neoplasia. Despite
Upper GI Screening Endoscopy in Individuals With a Family History of Barrett’s Esophagus or Esophageal Cancer
The incidence of esophageal adenocarcinoma (EAC) continues to increase and is still associated with a poor prognosis with a 5-year survival rate of 20%. The
Artificial Intelligence During Barrett’s Endoscopy Is Accurate for Reporting Prague Criteria
During endoscopy, the extent of Barrett’s esophagus (BE) is quantified by endoscopists using the widely accepted Prague C&M (circumferential and maximal lengths) criteria. Prague C&M
Only 80% Eradication Rates of Barrett’s Esophagus With Long-Term Follow-Up of Endoscopic Therapy Studies
Patients with high-grade dysplasia and/or early cancer in Barrett’s esophagus (BE) are treated with endoscopic therapy (BET), with the goal of complete eradication of all
One in 5 Upper GI Neoplastic Lesions Missed During Endoscopy
Endoscopic Features for Recognizing Buried Barrett’s Esophagus
Buried Barrett’s esophagus (BE) mucosa, or subsquamous intestinal metaplasia, is defined as intestinal metaplasia that is present under a lining of endoscopically intact squamous epithelium.
Achalasia Patients at Increased Risk for Esophageal Cancer
Achalasia can cause food retention, leading to bacterial overgrowth, irritation, and chronic inflammation, a proposed pathophysiological process that may lead to squamous cell carcinoma (SCC).
Nonendoscopic Screening for Barrett’s Esophagus: Are We There?
Upper endoscopy (EGD) with biopsy remains the gold standard for the diagnosis of Barrett’s esophagus (BE). Several nonendoscopic techniques (sponge, capsule) have utilized biomarkers, such
Radiographic Studies Unreliable for Polyp Detection in Patients With Incomplete Colonoscopy
Douglas K. Rex, MD, FASGE, reviewing Parsa N, et al. Gastrointest Endosc 2020 Feb 4. In a single U.S. center with a large experience performing